Locally acting, the LIDODERM® patch targets the damaged nerves that
discharge pain impulses
Works in the peripheral nervous system to provide relief where it's needed 

Significant pain reduction within 7 to 14 days11
Can be used alone or in conjunction with systemic therapy—without added
systemic side effects2,3,9,10

Acts topically with low risk of systemic side effects2,3
12-hour once-daily dosing up to 3 patches at a time12
When the LIDODERM® patch is used concomitantly with local anesthetic products, the amount absorbed from all formulations must be considered. The LIDODERM® patch should be used with caution in patients with severe hepatic disease and in those receiving antiarrhythmic or local anesthetic drugs.
During or immediately after treatment with the LIDODERM® patch, the skin at the site of treatment may develop eythema or edema or may be the locus of abnormal sensation. These reactions are generally mild and transient, resolving spontaneously within a few minutes to hours.


   
   
  The LIDODERM® patch is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product. The LIDODERM® patch should be used with caution in patients with severe hepatic disease and in those receiving antiarrhythmic or local anesthetic drugs.

* An open-label, 4-week, nonrandomized, multicenter study of PHN patients (N=332), designed to assess the effectiveness of the LIDODERM® patch and its impact on patient quality of life (QOL). Patients were asked to report how much pain interfered with QOL parameters using a 0-10 scale in which 0=no interference and 10=complete interference. QOL was measured by evaluating pain interference with general activity, mood, work, walking ability, relationships with other people, sleep, and enjoyment of life. Mean scores for pain interference with QOL were examined individually at each time point and were summed across all items to provide composite indices of pain interference with QOL at each time point. Most commonly reported adverse event in this study was localized rash, which was considered to be related to study treatment in majority of cases (12%).

References: 1. Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clin J Pain. 2002;18: 297-301. 2. Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain. 1999;80: 533-538. 3. Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain. 1996;65:39-44. 4. Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol Dis. 1998;5:209-227. 5. Byers MR, Bonica JJ. Peripheral pain mechanisms and nociceptor plasticity. In: Loeser JD, ed. Bonica's Management of Pain. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:26-29. 6. Galer BS. Neuropathic pain of peripheral origin: advances in pharmacologic treatment. Neurology. 1995;45(suppl 9):S17-S25; S35-S36. 7. Galer BS. Advances in the treatment of postherpetic neuralgia: the topical lidocaine patch. Today Ther Trends: 2000;18:1-20. 8. Panlilio LM, Christo PJ, Raja SN. Current management of postherpetic neuralgia. The Neurologist. 2002;8:339-350. 9. Data on File (Davies et al). 10. Data on File (Burch, F). 11. Katz NP, Gammaitoni AR, Davis MW, et al. Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial. Pain Med. 2002;3(4):1-10. 12. Lidoderm® Complete Prescribing Information. Chadds Ford, PA: Endo Pharmaceuticals Inc; 2002. 13. Data on File (24-hour PK study).

The LIDODERM® patch is a registered trademark of Hind Health, Inc.
Chadds Ford, Pennsylvania 19317
www.Endo.com 1-800-462-ENDO
www.lidoderm.com LD-1208/Dec 2003
© 2004 Endo Pharmaceuticals



Legal Notices | Privacy Disclosure
2004 Endo Pharmaceuticals
www.endo.com